Introduction- PSYCH: The Psychedelics As Medicine Report 3rd Edition

PSYCH is proud to bring you the third edition of The Psychedelics as Medicine Report, profiling all major psychedelic drugs, both naturally derived plant-based varieties such as psilocybin, ibogaine, ayahuasca and mescaline, along with those synthetically manufactured in laboratory settings, such as LSD (lysergic acid diethylamide), ketamine, MDMA (3,4-Methylenedioxymethamphetamine) and novel second-generation psychedelics.

A year after the release of the second edition in September 2020, the world is still grappling with the COVID-19 pandemic. All of us have collectively lived through unprecedented times as the world has stood still for more than a year. Not only was our physical health in danger, but the looming threat and months-long lockdowns has also had a severely negative impact on our collective mental health. At the same time, the immensely quick development of effective vaccines has offered us hope for the future. A future where we will not only be able to tackle threats from outside but will also be able to improve the mental health of billions.

Once given to more than 40,000 patients, psychedelics were banned from the practitioner’s office in the Convention on Psychotropic Substances of 1971. These political decisions were a result, not of the danger of psychedelics, but as a response to the ‘hippie’ counterculture of the 1960s. Soon after they were banned, research into psychedelics became all but impossible.

Now, 50 years later, we are in the midst of a psychedelic renaissance. A wave of high-quality research has prompted renewed interest in psychedelics as medicine. Whereas psychedelics may have never left the general public, they are now being rediscovered by researchers, entrepreneurs, investors, and before too long, patients.

Our fully updated report will present you with an expert overview of the market opportunity that psychedelics as medicine offer. It identifies the regulatory landscape and provides unique insights into consumer and healthcare providers’ attitudes, and outlines which psychedelics are poised to disrupt conventional treatments for a wide array of debilitating mental health conditions, affecting hundreds of millions of people worldwide.

Finally, it offers key insights into the extraordinary opportunities that psychedelics will present to early movers in this nascent industry, including interviews with pioneering agents already operating in the therapeutic psychedelic space.

We hope you enjoy reading the latest edition of The Psychedelics as Medicine Report.